6,256 results match your criteria Annals of hematology[Journal]


Blood type and outcomes in patients with COVID-19.

Ann Hematol 2020 Jul 12. Epub 2020 Jul 12.

Division of Vascular and Endovascular Surgery, Department of Surgery, Massachusetts General Hospital (MGH), 15 Parkman Street, Boston, MA, 02214-3117, USA.

This study aimed to determine if there is an association between ABO blood type and severity of COVID-19 defined by intubation or death as well as ascertain if there is variability in testing positive for COVID-19 between blood types. In a multi-institutional study, all adult patients who tested positive for COVID-19 across five hospitals were identified and included from March 6th to April 16th, 2020. Hospitalization, intubation, and death were evaluated for association with blood type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04169-1DOI Listing

Long non-coding RNAs and MYC association in hematological malignancies.

Ann Hematol 2020 Jul 4. Epub 2020 Jul 4.

Molecular Biology Laboratory, Ioannina University Hospital, Ioannina, Greece.

Long non-coding RNAs (lncRNAs) have an established role in cell biology. Among their functions is the regulation of hematopoiesis. They characterize the different stages of hematopoiesis in a more lineage-restricted expression pattern than coding mRNAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04166-4DOI Listing

Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study.

Ann Hematol 2020 Jul 3. Epub 2020 Jul 3.

Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Str. 1, 30625, Hannover, Germany.

Immunosuppressive therapy (IST) is administered to patients with acquired hemophilia A (AHA) to eradicate autoantibodies against coagulation factor VIII (FVIII). Data from registries previously demonstrated that IST is often complicated by adverse events, in particular infections. This pilot study was set out to assess the feasibility of reduced-intensity, risk factor-stratified IST. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04150-yDOI Listing

Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.

Ann Hematol 2020 Jul 3. Epub 2020 Jul 3.

Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04168-2DOI Listing

Bone marrow coexistence of chronic lymphocytic leukemia and Langerhans cell sarcoma.

Ann Hematol 2020 Jul 3. Epub 2020 Jul 3.

Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, Terni, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04167-3DOI Listing

Thalassemia in the emergency department: special considerations for a rare disease.

Ann Hematol 2020 Jul 3. Epub 2020 Jul 3.

Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

Thalassemia is characterized by a defect in the synthesis of one or more of the globin subunits of hemoglobin. This defect results in imbalance in the α/β-globin chain ratio, ineffective erythropoiesis, chronic hemolytic anemia, and iron overload. With advances in diagnosis, treatment, and transfusion support, the prognosis of patients with thalassemia has improved over the past few decades. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04164-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333588PMC

Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia.

Ann Hematol 2020 Jul 3. Epub 2020 Jul 3.

Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstraße 74, 01307, Dresden, Germany.

Resistant disease is still a main obstacle in acute myeloid leukemia (AML) treatment. Therefore, individual genetic variations affecting therapy response are gaining increasing importance. Both SNPs and ABC transporter genes could already be associated with drug resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04163-7DOI Listing

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.

Ann Hematol 2020 Aug 1;99(8):1793-1804. Epub 2020 Jul 1.

Hematology and Medical Oncology, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study (NCT02181413) demonstrated improved progression-free survival with ixazomib maintenance versus placebo post autologous stem cell transplant (ASCT) in multiple myeloma patients. We report additional safety data from TOURMALINE-MM3 to inform adverse event (AE) management recommendations. Patients were randomized 3:2 to receive ixazomib (n = 395) or placebo (n = 261) on days 1, 8, and 15 of 28-day cycles for ~ 2 years or until progressive disease/toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04149-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340660PMC

Statin use and the risk of multiple myeloma: a PRISMA-compliant meta-analysis.

Ann Hematol 2020 Aug 29;99(8):1805-1812. Epub 2020 Jun 29.

State Key Laboratory of Proteomics, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing, 100071, China.

Previous studies exploring associations between statin use and risk of multiple myeloma (MM) showed inconsistent results. We searched for articles published in English in databases (PubMed, Web of Science, EMBASE, Medline, and Google Scholar) before October 2019. The multivariate odds ratio (OR)/relative risk (RR) and 95% confidence intervals (CI) were computed to explore associations between statin use and risk of MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04157-5DOI Listing

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.

Ann Hematol 2020 Jul 1. Epub 2020 Jul 1.

Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria.

High-grade B cell lymphomas with rearrangements on C-MYC and BCL2 and/or BCL6 (HGBL with MYC and BCL2 and/or Bcl6 rearrangement) are associated with worse clinical outcomes and thus were introduced as a separate new category in the recently updated WHO classification. From 2012 to 2016, we analyzed a consecutive cohort of large B cell lymphomas (LBCLs) for C-MYC, BCL2, and BCL6 rearrangements and correlated our results with clinical-pathological parameters. Ten of 78 (13%) cases had a C-MYC and BCL2 and/or BCL6 rearrangement, so-called double or triple hit (DH), while double/triple copy number gains (CNGs) were found in eight (10%) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04124-0DOI Listing

Risk and impact of invasive fungal infections in patients with multiple myeloma.

Ann Hematol 2020 Aug 1;99(8):1813-1822. Epub 2020 Jul 1.

Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201 Shipai Road, Sec. 2, Taipei, 11217, Taiwan.

Infection is associated with great morbidity and mortality in patients with multiple myeloma (MM), but evidence for invasive fungal infections (IFIs) is lacking. We aimed to investigate risk factors for IFI in MM patients and to determine its impact on patients' survival. We retrospectively analyzed MM patients at Taipei Veterans General Hospital in Taiwan between January 2002 and October 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04125-zDOI Listing
August 2020
2.634 Impact Factor

Long-term follow-up of a novel immunosuppressive strategy of cyclosporine alternatively combined with levamisole for severe aplastic anemia.

Ann Hematol 2020 Aug 29;99(8):1727-1734. Epub 2020 Jun 29.

State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, People's Republic of China.

Hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CsA) have been widely accepted as the standard first-line treatments for severe aplastic anemia (SAA). However, most of the patients with SAA had a slim chance to access these strategies in developing countries. Here, we reported 10-year results in a cohort of 232 patients with SAA who received a novel IST of CsA, levamisole, and danazol (CsA&LMS-based regimen). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04153-9DOI Listing

Measures for preventing nosocomial infection with SARS-CoV-2 in hematology departments.

Ann Hematol 2020 08 29;99(8):1933-1938. Epub 2020 Jun 29.

Department of Hematology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04127-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323882PMC

Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T phase IB trial of the LYSA.

Ann Hematol 2020 Aug 29;99(8):1771-1778. Epub 2020 Jun 29.

Department of Hematology, CHU de Nantes, University Hospital of Nantes, Nantes, France.

Mantle cell lymphoma has a dismal prognosis at relapse or in the refractory setting. Among therapies, mTor pathway targeting by temsirolimus has been the first strategy approved for relapse in Europe. While its efficacy in monotherapy has long been demonstrated, its use remains limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04159-3DOI Listing

Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.

Ann Hematol 2020 Aug 27;99(8):1779-1791. Epub 2020 Jun 27.

Department of Hematology, The Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, The Second Military Medical University, 415 Fengyang Rd, Shanghai, 200003, China.

The Revised International Staging System (R-ISS) was introduced as a powerful prognostic system to stratify patients with newly diagnosed multiple myeloma (NDMM). The serum-free light chain (sFLC) has been developed as a valuable marker to monitor multiple myeloma (MM) progression and response. Therefore, it is imperative to combine R-ISS and sFLC prognostic factors as modified R-ISS (MR-ISS) to better stratify patients into homogeneous survival subgroups, especially to further distinguish the high-risk MM patients who are likely to experience rapid progression or relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04162-8DOI Listing

Gene mutation profile in patients with acquired pure red cell aplasia.

Ann Hematol 2020 Aug 27;99(8):1749-1754. Epub 2020 Jun 27.

Department of Hematology, Peking union medical college hospital, Chinese academy of medical sciences and Peking union medical college, Beijing, 100730, China.

Acquired pure red cell aplasia (PRCA) is a disorder characterized by normocytic anemia associated with reticulocytopenia and an absence of erythroblasts. The gene mutation profile in acquired PRCA is not defined yet. In this study, we aimed to identify the gene mutation spectrum of patients with acquired PRCA and the correlation between gene mutations and response to immunosuppressive therapy (IST). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04154-8DOI Listing

The FLAMSA concept-past and future.

Ann Hematol 2020 Jun 27. Epub 2020 Jun 27.

Medizinische Klinik Universitätsklinikum Augsburg, Stenglinstrasse 2, 86156, Augsburg, Germany.

The FLAMSA reduced intensity (RIC) concept, also known as "sequential therapy", is a conceptual platform for the treatment of leukemia separated in several parts: induction therapy, a sequence of antileukemic and immunosuppressive conditioning for allogeneic stem cell transplantation, and immune restitution supported by donor lymphocyte transfusions. The antileukemic part consists of fludarabine, cytosine arabinoside, and amsacrine (FLAMSA); non-cross reactive agents like fludarabine and amsacrine have been successfully used in cases of refractoriness and relapse. Immunosuppressive conditioning and transplantation follow after only 3 days of rest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04131-1DOI Listing

Long non-coding RNA CCAT2 as a potential serum biomarker for diagnosis and prognosis of multiple myeloma.

Ann Hematol 2020 Jun 26. Epub 2020 Jun 26.

Department of Laboratory Medicine, Affiliated Hospital of Nantong University, No 20, Xisi Road, Nantong, 226001, China.

Increasing knowledge of long non-coding RNAs (lncRNAs) has shown that they can be used as circulating tumor markers. Also, considerable evidences have revealed that lncRNAs have important roles in tumor diagnosis and prognosis. The lncRNA CCAT2 has manifested its carcinogenic effect in a variety of tumors, but the serum expression level and clinical value in multiple myeloma (MM) remain to be explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04161-9DOI Listing

SARS-CoV-2-associated cold agglutinin disease: a report of two cases.

Ann Hematol 2020 08 26;99(8):1943-1944. Epub 2020 Jun 26.

Department of Internal Medicine, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, University of Paris, 2 rue Ambroise Paré, 75010, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04129-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317069PMC

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.

Ann Hematol 2020 Jun 25. Epub 2020 Jun 25.

Hematology, "Cardarelli" Hospital, Naples, Italy.

From April 2016, carfilzomib, in combination with lenalidomide and dexamethasone (KRD), became available for use in the daily practice in Italy for patients with relapsed or refractory multiple myeloma (RRMM). We performed a retrospective survey at 14 different institutions from Southern Italy in order to evaluate patient characteristics and treatment results from an unselected series of patients treated accordingly so far. One hundred and twenty-three consecutive patients were included, with a median of 2 previous lines of therapy (range 1-9) and a median age of 63 years (range 39-82). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04158-4DOI Listing

COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.

Authors:
Monia Marchetti

Ann Hematol 2020 Aug 24;99(8):1701-1707. Epub 2020 Jun 24.

Hematology Department, Az Osp SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

COVID-19 pandemia is a major health emergency causing hundreds of deaths worldwide. The high reported morbidity has been related to hypoxia and inflammation leading to endothelial dysfunction and aberrant coagulation in small and large vessels. This review addresses some of the pathways leading to endothelial derangement, such as complement, HIF-1α, and ABL tyrosine kinases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04138-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312112PMC

Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.

Ann Hematol 2020 Jun 23. Epub 2020 Jun 23.

Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04152-wDOI Listing

Detection of the MYD88 and CXCR4 mutations by cell-free DNA in Waldenström macroglobulinemia.

Ann Hematol 2020 Aug 23;99(8):1763-1769. Epub 2020 Jun 23.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.

We aimed to detect the MYD88 and CXCR4 mutations in cell-free DNA (cfDNA) in patients with Waldenström macroglobulinemia (WM). We collected peripheral blood and paired bone marrow aspirates from 27 WM patients (including 16 patients with newly diagnosed WM, 3 patients with WM in relapse and 8 patients with WM during treatment). cfDNA was extracted from peripheral blood using a QIAamp Circulating Nucleic Acid Kit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04139-7DOI Listing

Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.

Ann Hematol 2020 Aug 23;99(8):1823-1831. Epub 2020 Jun 23.

Medical Research Center, Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Kajaanintie 50, P.O. Box 5000, 900l4, Oulu, Finland.

Although overall survival in diffuse large B cell lymphomas (DLBCL) has improved, central nervous system (CNS) relapse is still a fatal complication of DLBCL. For this reason, CNS prophylaxis is recommended for patients at high risk of CNS disease. However, no consensus exists on definition of high-risk patient and optimal CNS prophylaxis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04140-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340636PMC

Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation.

Ann Hematol 2020 Aug 23;99(8):1833-1843. Epub 2020 Jun 23.

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.

Monosomal karyotype (MK) is associated with poor prognosis in patients with myeloid neoplasms; however, its prognostic significance in Philadelphia chromosome-negative (Ph-negative) acute lymphoblastic leukemia (ALL) remains unclear. Data of 323 patients with Ph-negative ALL treated at Peking University People's Hospital were retrospectively analyzed. MK was identified in 49 (14. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04155-7DOI Listing

Kostmann's disease or severe hereditary neutropenia-the man behind the syndrome.

Ann Hematol 2020 Jun 23. Epub 2020 Jun 23.

Department of Pediatrics and Department of Clinical and Experimental Medicine, Norrköping Hospital, Linköping University, SE-60182, Norrköping, Sweden.

Seventy years ago, the Swedish pediatrician Rolf Kostmann (1909-1982) was the first to report on a previous unknown lethal hereditary neutropenia in infants, Kostmann's disease. This essay presents the man behind the syndrome rather than focusing on the disease itself. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04142-yDOI Listing

Liver damage and sickle cell disease: genotype relationship.

Ann Hematol 2020 Jun 22. Epub 2020 Jun 22.

Unità di Medicina Generale, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122, Milan, Italy.

Sickle hepatopathy is a severe and not rare complication of sickle cell disease (SCD), showing mainly a cholestatic pattern. So far, no effective approaches to prevent or treat this condition have been recognized. We conducted a single-center observational study in 68 adult sickle cell patients, encompassing 17 with sickle cell anemia (SCA), 38 with sickle cell thalassemia (HbS/β-Thal), and 13 with HbSC disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04113-3DOI Listing

Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.

Ann Hematol 2020 Aug 22;99(8):1883-1893. Epub 2020 Jun 22.

Department of Hematology, Chinese PLA General Hospital, Beijing, 100853, China.

In allogeneic hematopoietic stem cell transplantation recipients, cytomegalovirus (CMV) infection can cause overt CMV-associated disease, which is a main cause of transplantation-associated mortality. CMV infection correlates closely with donor's type. We therefore examined whether risk factors of CMV reactivation and clinical endpoints in patients with hematologic malignancies after allogeneic peripheral blood stem cell transplantation (PBSCT) differed between using matched-sibling donors (MSD-SCT) and haploidentical donors (HID-SCT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04156-6DOI Listing

Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma.

Ann Hematol 2020 Jun 22. Epub 2020 Jun 22.

Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.

The amount of infused CD34 cells has been reported to be the strongest predictor of platelet recovery after autologous stem cell transplantation (ASCT). However, the timing of platelet recovery varies widely among patients even after the infusion of similar amounts of CD34 cells. Therefore, we retrospectively assessed 99 patients who underwent their first ASCT for lymphoma or myeloma at our center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04112-4DOI Listing
June 2020
2.634 Impact Factor

UNC0638 induces high levels of fetal hemoglobin expression in β-thalassemia/HbE erythroid progenitor cells.

Ann Hematol 2020 Jun 21. Epub 2020 Jun 21.

Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, 25/25 Phuttamonthon 4 Road, Salaya, Nakhon Pathom, 73170, Thailand.

Increased expression of fetal hemoglobin (HbF) improves the clinical severity of β-thalassemia patients. EHMT1/2 histone methyltransferases are epigenetic modifying enzymes that are responsible for catalyzing addition of the repressive histone mark H3K9me2 at silenced genes, including the γ-globin genes. UNC0638, a chemical inhibitor of EHMT1/2, has been shown to induce HbF expression in human erythroid progenitor cell cultures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04136-wDOI Listing

Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC.

Ann Hematol 2020 Aug 20;99(8):1855-1862. Epub 2020 Jun 20.

Department of Hematology, CHU Hôtel Dieu, Place A. Ricordeau, 44093, Nantes Cedex, France.

Allogeneic stem cell transplantation (allo-SCT) represents the most beneficial treatment for patients with active relapsed/refractory (R/R) hematologic malignancies. Recently, sequential regimens combining debulking chemotherapy followed by reduced-intensity conditioning (RIC) have shown encouraging results for these patients. In this retrospective study, we report the extended results of a sequential regimen of clofarabine, cytosine arabinoside, and RIC in 131 adults with active R/R myeloid disease at transplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04074-7DOI Listing

Safety of bedside lumbar puncture in adult patients with thrombocytopenia.

Ann Hematol 2020 Aug 20;99(8):1755-1762. Epub 2020 Jun 20.

Department of Medicine, University of Rochester Medical Center, Box MED, 601 Elmwood Ave., Rochester, NY, 14642, USA.

The risk of lumbar puncture (LP) hemorrhagic complications is believed to be exacerbated by thrombocytopenia, yet evaluations in clinical practice are lacking. We conducted a retrospective cohort study to examine the risk of traumatic tap (TT) and significant hemorrhagic complications in thrombocytopenic patients undergoing bedside LP. Two hundred sixty-two adult patients undergoing initial bedside LP were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04148-6DOI Listing

An eleven-year cohort of bloodstream infections in 552 febrile neutropenic patients: resistance profiles of Gram-negative bacteria as a predictor of mortality.

Ann Hematol 2020 Aug 20;99(8):1925-1932. Epub 2020 Jun 20.

Department of Infectious Diseases and Clinical Microbiology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, 34098, Istanbul, Turkey.

Antimicrobial stewardship is of major importance in patients with febrile neutropenia (FN). In this study, we aimed to investigate the trends in resistance and the relationship with mortality rates in patients with FN. The single-center surveillance data of inpatients with FN and diagnosed as microbiologically confirmed bloodstream infections (BSIs) between 2006 and 2016 were reviewed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04144-wDOI Listing

Disseminated infection with novel human adenovirus (genotype 79) following allogeneic hematopoietic stem cell transplantation.

Ann Hematol 2020 Jun 18. Epub 2020 Jun 18.

Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04151-xDOI Listing

Sustained remission of giant pancreatic plasmacytoma with daratumumab.

Ann Hematol 2020 Jun 18. Epub 2020 Jun 18.

Department of Hematology, Tohoku University Hospital, 1-1 Seiryo-cho, Sendai, 980-8574, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04145-9DOI Listing

Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.

Ann Hematol 2020 Jun 17. Epub 2020 Jun 17.

Hematology Department, University hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04143-xDOI Listing

De-escalation of empiric broad spectrum antibiotics in hematopoietic stem cell transplant recipients with febrile neutropenia.

Ann Hematol 2020 Aug 17;99(8):1917-1924. Epub 2020 Jun 17.

Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, 985400 Nebraska Medical Center, Omaha, NE, 68198-5400, USA.

Febrile neutropenia (FN) is a common serious complication in patients undergoing hematopoietic stem cell transplantation (HSCT) requiring urgent evaluation and initiation of empiric broad spectrum antibiotics (BSA). The appropriate duration of BSA for FN in patients with negative cultures and no identifiable infection remains undefined. We retrospectively analyzed allogenic and autologous HSCT patients with FN and negative infectious work-up at our facility from 2012 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04132-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340662PMC

Type I congenital methemoglobinemia in a Chinese family.

Ann Hematol 2020 Jun 17. Epub 2020 Jun 17.

Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04141-zDOI Listing

Outcomes of allogeneic haematopoietic stem cell transplantation for patients with severe aplastic anaemia using the porcine antilymphocyte globulin-containing conditioning regimen.

Ann Hematol 2020 Aug 17;99(8):1863-1871. Epub 2020 Jun 17.

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-fang Avenue, Wuhan, Hubei, 430030, People's Republic of China.

Antithymocyte globulin (ATG) is widely used for allogeneic haematopoietic stem cell transplantation (allo-HSCT) in severe aplastic anaemia (SAA). Only rabbit-ATG (r-ATG) and porcine-antilymphocyte globulin (p-ALG) are available in China, but the p-ALG-containing conditioning regimen for allo-HSCT in SAA has seldom been reported. In this study, we retrospectively evaluated the outcomes of 41 SAA patients receiving allo-HSCT with a p-ALG-containing conditioning regimen in our transplantation centre. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04111-5DOI Listing

Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up.

Ann Hematol 2020 Jun 15. Epub 2020 Jun 15.

Royal Brompton Hospital, London, UK.

The consequence of regular blood transfusion in patients with thalassemia major (TM) is iron overload. Herein, we report the long-term impact of chelation on liver iron concentration (LIC) and cardiac T2* MR in patients with TM. This is a retrospective cohort study over 10 years of adolescents and adults with TM aged at least 10 years who had their first cardiac T2* MR between September 2006 and February 2007. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04117-zDOI Listing

Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia.

Ann Hematol 2020 Jun 16. Epub 2020 Jun 16.

Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Rue du Bugnon 46, Lausanne, CH-1011, Switzerland.

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases, with a variable probability of transformation into acute leukemia, which is, in the vast majority of cases, of myeloid lineage. Nevertheless, rare cases of acute lymphoblastic leukemia in patients with previously diagnosed MDS have been reported. We describe a series of 3 cases of MDS/CMML marked with evolution to acute lymphoblastic leukemia (ALL) and provide a comprehensive review of the 49 cases documented in the literature so far. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04114-2DOI Listing

Bortezomib and rituximab in multiply relapsed primary warm autoimmune hemolytic anemia.

Ann Hematol 2020 Jun 17. Epub 2020 Jun 17.

Dumfries & Galloway Royal Infirmary, Dumfries, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04135-xDOI Listing

Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL.

Ann Hematol 2020 Jun 16. Epub 2020 Jun 16.

Department of Medicine, University of Washington Medical Center, 825 Eastlake Ave E, Seattle, WA, 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04091-6DOI Listing
June 2020
2.634 Impact Factor

COVID-19 infection associated with autoimmune hemolytic anemia.

Ann Hematol 2020 Jul 16;99(7):1679-1680. Epub 2020 Jun 16.

Department of Intensive Care, Cliniques St-Luc, Université catholique de Louvain, Avenue Hippocrate, 10, 1200, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04137-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295688PMC

Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab.

Ann Hematol 2020 Jul 15;99(7):1493-1503. Epub 2020 Jun 15.

Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, 73, Goryeodae-ro, Seongbuk-gu, Seoul, 02841, South Korea.

Eculizumab is effective in managing patients with paroxysmal nocturnal hemoglobinuria (PNH). In South Korea, the financial support for eculizumab therapy is extended by the National Health Insurance Services (NHIS) only to patients with high-risk PNH for approximately 10 years. In this study, we performed a nationwide analysis of the real-world efficacy of eculizumab therapy in patients diagnosed with PNH between January 1, 2002, and December 31, 2016, by using the NHIS database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04133-zDOI Listing

Behҫet-like syndrome associated with aplastic anemia successfully treated with mycophenolate mofetil.

Ann Hematol 2020 Jun 13. Epub 2020 Jun 13.

Department of Internal Medicine, General Hospital of Šibenik-Knin County, Stjepana Radića 83, 22000, Šibenik, Croatia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04119-xDOI Listing

Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients.

Ann Hematol 2020 Aug 13;99(8):1735-1740. Epub 2020 Jun 13.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, ,100730, Beijing, People's Republic of China.

To explore the clinical characteristics and outcomes in Chinese patients with type I cryoglobulinemia (CG), we retrospectively analyzed the clinical data, management, and outcomes of 45 patients diagnosed with type I CG in our hospital from January 2015 to March 2019. In our study, all type I CGs were secondary to hematologic diseases, and monoclonal gammopathy of unknown significance was the most common primary disease, accounting for 48.9% (n = 22). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04123-1DOI Listing

COVID-19 presenting as neutropenic fever.

Ann Hematol 2020 08 13;99(8):1939-1940. Epub 2020 Jun 13.

Department of Medicine, Oregon Health & Science University, 7310, 3245 SW Pavilion Loop, Portland, OR, 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04128-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292938PMC